Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.87 | 1.36 |
NAV | ₹789.20 | ₹201.58 |
Fund Started | 10 Sep 2002 | 07 May 2007 |
Fund Size | ₹6271.07 Cr | ₹92168.85 Cr |
Exit Load | Exit load of 1%, if redeemed within 90 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -1.13% | 3.99% |
3 Year | 18.55% | 24.02% |
5 Year | 20.73% | 25.61% |
1 Year
3 Year
5 Year
Equity | 98.26% | 93.94% |
Cash | 1.74% | 6.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
AU Small Finance Bank Ltd. | 3.93% |
Max Financial Services Ltd. | 3.02% |
The Federal Bank Ltd. | 2.82% |
APL Apollo Tubes Ltd. | 2.73% |
K.P.R. Mill Ltd. | 2.56% |
Prestige Estates Projects Ltd. | 2.55% |
Thermax Ltd. | 2.53% |
Torrent Power Ltd. | 2.31% |
JK Cement Ltd. | 2.18% |
Mphasis Ltd. | 2.14% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.46% |
AU Small Finance Bank Ltd. | 3.70% |
Indian Bank | 3.54% |
The Federal Bank Ltd. | 3.38% |
Balkrishna Industries Ltd. | 3.37% |
Fortis Healthcare Ltd. | 3.19% |
Coforge Ltd. | 3.11% |
Hindustan Petroleum Corporation Ltd. | 2.96% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Ipca Laboratories Ltd. | 2.52% |
Name | Dhaval Joshi | Chirag Setalvad |
Start Date | 10 Jun 2024 | 28 Jun 2014 |
Name
Start Date
Description | The scheme aims at long-term growth of capital at controlled level of risk by investing primarily in mid-cap stocks, to generate returns higher than a fund focused on large and liquid stocks. A small portion of the portfolio may be kept in call & money market instruments in order to meet the liquidity needs. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 10 Sep 2002 | 07 May 2007 |
Description
Launch Date